Bailard, Inc. Gilead Sciences, Inc. Transaction History

Bailard, Inc.

$3.58 Billion
Q1 2024

A detailed history of Bailard, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Bailard, Inc. holds 672,641 shares of GILD stock, worth $44.8 Million. This represents 1.38% of its overall portfolio holdings.

Number of Shares

672,641

Previous 673,507 0.13%

Holding current value

$44.8 Million

Previous $54.6 Million 9.7%

% of portfolio

1.38%

Previous 1.63%

35 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	SELL	$71.58 - $87.29 $61,988 - $75,593	-866 Reduced 0.13%	672,641 $49.3 Million
Q4 2023 Feb 02, 2024	SELL	$73.27 - $83.09 $3.58 Million - $4.06 Million	-48,838 Reduced 6.76%	673,507 $54.6 Million
Q3 2023 Oct 24, 2023	BUY	$73.94 - $80.67 $52.8 Million - $57.6 Million	714,494 Added 9100.68%	722,345 $54.1 Million
Q2 2023 Jul 20, 2023	SELL	$76.01 - $86.7 $63,012 - $71,874	-829 Reduced 9.55%	7,851 $605,000
Q1 2023 May 08, 2023	SELL	$77.31 - $88.08 $10,127 - $11,538	-131 Reduced 1.49%	8,680 $720,000

Q4 2022 Feb 02, 2023	SELL	$62.32 - $89.47 $118,221 - $169,724	-1,897 Reduced 17.72%	8,811 $756,000
Q3 2022 Oct 18, 2022	BUY	$59.54 - $68.01 $76,925 - $87,868	1,292 Added 13.72%	10,708 $661,000
Q2 2022 Jul 27, 2022	BUY	$57.72 - $65.01 $14,545 - $16,382	252 Added 2.75%	9,416 $582,000
Q1 2022 Apr 25, 2022	SELL	$57.92 - $72.58 $40,080 - $50,225	-692 Reduced 7.02%	9,164 $545,000
Q4 2021 Feb 10, 2022	SELL	$64.88 - $73.64 $38,149 - $43,300	-588 Reduced 5.63%	9,856 $716,000
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $133,281 - $143,796	1,969 Added 23.23%	10,444 $730,000
Q2 2021 Aug 13, 2021	SELL	$63.47 - $69.35 $338,231 - $369,566	-5,329 Reduced 38.6%	8,475 $584,000
Q1 2021 May 13, 2021	SELL	$60.0 - $68.46 $37,560 - $42,855	-626 Reduced 4.34%	13,804 $892,000
Q4 2020 Feb 03, 2021	BUY	$56.65 - $64.55 $117,832 - $134,264	2,080 Added 16.84%	14,430 $841,000
Q3 2020 Nov 10, 2020	BUY	$62.1 - $78.08 $102,899 - $129,378	1,657 Added 15.5%	12,350 $780,000
Q2 2020 Aug 12, 2020	SELL	$72.34 - $84.0 $4.3 Million - $4.99 Million	-59,434 Reduced 84.75%	10,693 $823,000
Q1 2020 Apr 16, 2020	BUY	$62.63 - $80.22 $586,467 - $751,180	9,364 Added 15.41%	70,127 $5.24 Million
Q4 2019 Jan 31, 2020	SELL	$61.62 - $67.78 $3.65 Million - $4.02 Million	-59,307 Reduced 49.39%	60,763 $3.95 Million
Q3 2019 Oct 18, 2019	BUY	$62.51 - $69.0 $4.41 Million - $4.87 Million	70,558 Added 142.51%	120,070 $7.61 Million
Q2 2019 Jul 26, 2019	SELL	$61.87 - $69.38 $3,279 - $3,677	-53 Reduced 0.11%	49,512 $3.35 Million
Q1 2019 Apr 24, 2019	BUY	$62.53 - $70.05 $370,740 - $415,326	5,929 Added 13.59%	49,565 $3.22 Million
Q4 2018 Feb 05, 2019	SELL	$60.54 - $79.0 $153,226 - $199,949	-2,531 Reduced 5.48%	43,636 $2.73 Million
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $96,370 - $106,699	-1,352 Reduced 2.85%	46,167 $3.57 Million
Q2 2018 Aug 08, 2018	BUY	$64.88 - $75.68 $59,624 - $69,549	919 Added 1.97%	47,519 $3.37 Million
Q1 2018 May 07, 2018	BUY	$72.84 - $88.8 $620,451 - $756,398	8,518 Added 22.37%	46,600 $3.51 Million
Q4 2017 Feb 08, 2018	SELL	$71.15 - $83.52 $476,278 - $559,082	-6,694 Reduced 14.95%	38,082 $0
Q3 2017 Oct 11, 2017	SELL	$72.11 - $85.47 $269,475 - $319,401	-3,737 Reduced 7.7%	44,776 $3.63 Million
Q2 2017 Aug 11, 2017	BUY	N/A	806 Added 1.69%	48,513 $0
Q1 2017 Jan 29, 2018	BUY	N/A	787 Added 1.68%	47,707 $3.24 Million
Q4 2016 Jan 29, 2018	SELL	N/A	-2,247 Reduced 4.57%	46,920 $0
Q3 2016 Jan 29, 2018	BUY	N/A	21,398 Added 77.06%	49,167 $3.89 Million
Q2 2016 Jan 29, 2018	BUY	N/A	24,110 Added 658.92%	27,769 $0
Q1 2016 Jan 29, 2018	SELL	N/A	-2,341 Reduced 39.02%	3,659 $336,000
Q4 2015 Jan 29, 2018	SELL	N/A	-13,202 Reduced 68.75%	6,000 $0
Q3 2015 Jan 29, 2018	BUY	N/A	19,202	19,202 $1.89 Million

Others Institutions Holding GILD

# of Institutions

1,885

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $83.5B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bailard, Inc. with notifications on news.

Account